BioNexus Gene Lab Corp. (BGLC)

Every figure this model derived for BGLC, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

The ratios

The figures themselves rather than their scores — what somebody looking up BGLC on one particular measure came for.

Everything else this filing tags

296 more elements from BGLC's own XBRL that this model has no measure for, newest reading each, largest first. Nothing here is converted, added up or renamed — it is the filing's own element names and the filing's own numbers.

What to be careful about

What this model itself distrusts about BGLC's figures. Written by the derivation as it ran, not added afterwards.

• no usable diluted share count, so growth is measured on total revenue rather than per share; a company issuing shares to fund that growth reads better than it is
• there is no operating profit to value; valuation rests on EV/revenue (0.9x) instead
• analyst estimate not used: trailing EPS is not positive, so a growth rate would be meaningless
• durability rests on 3 of 4 inputs; not tagged: contracted coverage